Multispectral Optoacoustic Tomography for Advanced Imaging of Centronuclear Myopathy

RecruitingOBSERVATIONAL
Enrollment

40

Participants

Timeline

Start Date

May 29, 2025

Primary Completion Date

October 31, 2025

Study Completion Date

December 31, 2026

Conditions
Centronuclear Myopathy
Interventions
DIAGNOSTIC_TEST

MSOT

Multispectral optoacoustic tomography (MSOT) enables the detection of specific endogenous chromophores such as collagen, myoglobin or haemoglobin using a non-invasive approach comparable to conventional ultrasound. Instead of sound waves, MSOT illuminates the tissue with near-infrared light of transient energy, which is absorbed and leads to thermoelastic expansion of certain molecules. This expansion generates ultrasound waves that are detected by the same device. The multispectral illumination and unmixing then enable the precise localization and quantification of muscle-specific subcellular structures. MSOT has already shown the potential to visualize the muscle structure and clinical extent of muscle disease in patients with Duchenne muscular dystrophy, spinal muscular atrophy and the late-onset Pompe disease (LOPD) and to distinguish these patients from healthy volunteers. To date, there is no optoacoustic data on CNM.

Trial Locations (1)

91054

RECRUITING

Uniklinikum Erlangen, Erlangen

All Listed Sponsors
lead

University of Erlangen-Nürnberg Medical School

OTHER

NCT07021820 - Multispectral Optoacoustic Tomography for Advanced Imaging of Centronuclear Myopathy | Biotech Hunter | Biotech Hunter